Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 6931 AL 6945

Acylhydrazones and Their Biological Activity: A Review

Socea LI, Barbuceanu SF, Pahontu EM, Dumitru AC, Nitulescu GM, Sfetea RC, Apostol TV.

Molecules. 2022 Dec 9;27(24):8719. doi: 10.3390/molecules27248719.

Targeting the Nrf2 signaling pathway using phytochemical ingredients: A novel therapeutic road map to combat neurodegenerative diseases

Bai X, Bian Z, Zhang M.

Phytomedicine. 2023 Jan;109:154582. doi: 10.1016/j.phymed.2022.154582. Epub 2022 Nov 30.

Rivastigmine improves dual-task gait velocity in patients with Alzheimer's disease

Shimura H, Saiko A, Hayashi A, Hattori N, Urabe T.

BMC Neurol. 2021 Feb 10;21(1):61. doi: 10.1186/s12883-021-02098-8.

Melatonin Receptor as a Drug Target for Neuroprotection

Wongprayoon P, Govitrapong P.

Curr Mol Pharmacol. 2021;14(2):150-164. doi: 10.2174/1874467213666200421160835.

Current Updates in Transdermal Therapeutic Systems and Their Role in Neurological Disorders

Yadav N, Mittal A, Ali J, Sahoo J.

Curr Protein Pept Sci. 2021;22(6):458-469. doi: 10.2174/1389203721999201111195512.

Cognitive Impairment in Older Adults and Therapeutic Strategies

Montine TJ, Bukhari SA, White LR.

Pharmacol Rev. 2021 Jan;73(1):152-162. doi: 10.1124/pharmrev.120.000031.

Advances in Stem Cell Therapy for Brain Diseases via the Intranasal Route

Dali P, Shende P.

Curr Pharm Biotechnol. 2021;22(11):1466-1481. doi: 10.2174/1389201021666201218130947.

Parkinson´s and Alzheimer´s Diseases and Natural Products: Pathologies and Medication of the New Times

Nabavi SM, Sobarzo-Sánchez E.

Curr Neuropharmacol. 2021;19(2):112-113. doi: 10.2174/1570159X1902201231153120.

The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models

MacDougall G, Brown LY, Kantor B, Chiba-Falek O.

Mol Ther. 2021 Mar 3;29(3):949-972. doi: 10.1016/j.ymthe.2021.01.001. Epub 2021 Jan 9.

GSK-3 Inhibitors: A New Class of Drugs for Alzheimer's Disease Treatment

Pal D, Mukherjee S, Song IH, Nimse SB.

Curr Drug Targets. 2021;22(15):1725-1737. doi: 10.2174/1389450122666210114095307.

Deep Brain Stimulation in Alzheimer's Disease: Targeting the Nucleus Basalis of Meynert

Chen YS, Shu K, Kang HC.

J Alzheimers Dis. 2021;80(1):53-70. doi: 10.3233/JAD-201141.

Recent Advances in the Discovery of GSK-3 Inhibitors from Synthetic Origin in the Treatment of Neurological Disorders

Saha S, Pal D, Nimse SB.

Curr Drug Targets. 2021;22(12):1437-1462. doi: 10.2174/1389450122666210120143953.

A Novel Treatment Strategy by Natural Products in NLRP3 Inflammasome-Mediated Neuroinflammation in Alzheimer's and Parkinson's Disease

Lee JH, Kim HJ, Kim JU, Yook TH, Kim KH, Lee JY, Yang G.

Int J Mol Sci. 2021 Jan 28;22(3):1324. doi: 10.3390/ijms22031324.

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia

Parsons C, Lim WY, Loy C, McGuinness B, Passmore P, Ward SA, Hughes C.

Cochrane Database Syst Rev. 2021 Feb 3;2(2):CD009081. doi: 10.1002/14651858.CD009081.pub2.

Neuropeptides: Roles and Activities as Metal Chelators in Neurodegenerative Diseases

Ben-Shushan S, Miller Y.

J Phys Chem B. 2021 Mar 25;125(11):2796-2811. doi: 10.1021/acs.jpcb.0c11151. Epub 2021 Feb 11.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias